Filing Flows › Health Care › Dare Bioscience (DARE)
Dare Bioscience (DARE) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Dare Bioscience (DARE) Q2 2026 earnings results →
Dare Bioscience made $188K in Q2 2026. Operating margin n/m, net loss $3.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $188K in Q2 2026, up 23% from the previous quarter.
Operating costs exceeded revenue by $3.0M, an operating margin of -1582.5%. The quarter ended with a net loss of $3.0M, narrower than the previous quarter's $3.0M loss.
Operating cash flow was −$6.8M. Non-cash charges added back $572K of depreciation and amortization and $287K of share-based compensation. Working capital and other items used $4.7M. Capital expenditures of $81K exceeded it, leaving free cash flow of −$6.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $188K | — | n/m | −$3.0M | −$6.8M |
| Q1 2026 | 10-Q | May 14, 2026 | $152K | +500% | n/m | −$3.0M | −$5.5M |
| Q4 2025 | 10-K | Mar 26, 2026 | $1.0M | — | -143.7% | −$1.4M | $1.4M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $2K | -95% | n/m | −$3.6M | −$442K |
| Q1 2025 | 10-Q | May 13, 2025 | $25K | +173% | n/m | −$4.4M | −$5.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Dare Bioscience
The terms “we,” “us,” “our,” “Daré” or the “Company” refer collectively to Daré Bioscience, Inc. and its wholly-owned subsidiaries, unless otherwise stated or the context otherwise requires. All information in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years. We are a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs.
In its own words, from its 10-K, filed Mar 26, 2026.
Dare Bioscience against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DARE Dare Bioscience | Q2 2026 | $188K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Dare Bioscience 10-Q on SEC EDGAR · CIK 1401914 · Pharmaceutical Preparations
13F: who owns DARE and who is buying
More on DARE
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q1 2025 results